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Abstract
Background: Although the first clinical descriptions of Bartonella infection were associated with
immunocompromised patient with bacillary angiomatosis, we currently know that this organism is
directly involved in diseases affecting a large number of patients, regardless of their immune status.
Cat scratch disease, hepatic peliosis, and some cases of bacteraemia and endocarditis, are directly
caused by some species of the genus Bartonella. The purpose of this study was to determinate the
prevalence of IgG antibodies against Bartonella henselae and B. quintana in HIV patients and to
identify the epidemiological factors involved.
Methods: Serum samples were collected from HIV patients treated at Hospital de Sabadell.
Antibodies to B. henselae and  B. quintana from 340 patients were examined by indirect
immunofluorescence assay (IFA). Significance levels for univariate statistical test were determined
by the Mann-Whitney U test and χ2 test.
Results: Of 340 patients, 82 were women and 258 men, with a median age of 42.21 ± 10.35 years
(range 16–86 years). Seventy-six (22.3%) patients reacted with one or more Bartonella antigens. Of
all the factors concerning the seroprevalence rate being studied (age, sex, intravenous drugs use,
alcohol consumption, CD4 levels, AIDS, HCV, HBV, residential area), only age was statistically
significant.
Conclusion: A high percentage of HIV patients presents antibodies to Bartonella and is increasing
with age.
Background
The spectrum of Bartonella infections has expanded rap-
idly since the first HIV- infected patient with unusual, vas-
cular proliferative lesions of bacillary angiomatosis (BA)
was described in 1983 [1]. Of the 19 species of Bartonella
described until now, only 10 were acknowledged as
human pathogen species; B. bacilliformis, B. quintana, and
B. henselae, are the most frequently described species [2-
4], while B. elizabethae, B. vinsonii, B. washoensis, B. gra-
hamii, B. clarridgeiae, B. koehlerae and B. alsatica were
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recently identified as responsible for a few cases of human
infections [5-10]. Cat scratch disease (CSD), hepatic
peliosis and some cases of bacteraemia and endocarditis
are directly caused by some species of the genus Bartonella
[11-14]. To determine the real incidence of Bartonella
infections, we must study the seroprevalence in the gen-
eral population and the principal reservoirs and vectors of
infection transmission. The results yielded by different
studies on seroprevalence vary depending on the type of
population under study; thus, the research conducted on
collective groups that present special characteristics or
associated risk factors present a higher prevalence than
that found in studies carried out on the normal popula-
tion.
In patients with addiction to parenteral drugs, it ranged
from 15% to 47.5% [15,16]; in patients with HIV infec-
tion, it varied between 17.3% and 40% [17,18]. The
objective of this study was to evaluate the prevalence of
Bartonella infections in patients with HIV in our catch-
ment area and to assess related factors.
Methods
Geographical area
The study was undertaken in Vallès Occidental (Catalo-
nia), a predominantly urban area near the coast in the
northeast of Spain.
Samples
The collection of samples took place over a 10-month
period, from October 2004 to July 2005. The sample
included adults and children treated at Hospital de
Sabadell (Vallès Occidental, an area near Barcelona,
Spain), where most of the patients diagnosed with HIV
from the region are treated (cathment area 407.763
inhabitants). They were attended in periodical CD4 fol-
low-up. Serum samples were collected from these patients
at their scheduled follow up visits. The residential area
was determined considering the number of inhabitants
who lived in the municipalities. In fact, municipalities
with < 50.000 inhabitants were considered semirural
areas, and >50.000 were regarded as urban areas. Demo-
graphic information was obtained from computerized
clinic record. Information about alcoholism, drug use,
CD4 levels, HCV and HBV serology, was available from
computerized records for patients who regularly received
care at the clinic and was obtained by chart review for
some patients. Informed consent was obtained from adult
participants and from the parents of minors.
Serological technique
The sample of heparinized blood was sedimented (cen-
trifugation of 5 ml samples of blood at 1.500 rpm for 10
minutes), and the supernatant was collected and stored at
-80°C until used. Human serum samples were evaluated
by indirect immunofluorescence assay (IFA). We used
commercial slides (Bartonella IFA IgG. Focus Technolo-
gies, Inc., Herndon, VA) to determine antibodies to Bar-
tonella  spp. The kit for detecting IgG antibodies that
employees Vero cells infected with either B. henselae or B.
quintana was used according to the manufacturer's instruc-
tions. The serum samples were initially diluted 1/64. Any
serum samples found to be positive at the initial dilution
were further titrated. Positive and negative controls were
included in each test. We considered specimens showing
no fluorescence at IgG titers of 1/64 as negatives and spec-
imens with bright fluorescence in a dilution of 1/64 or
greater as positive. The intensity of each specific fluores-
cent test was subjectively evaluated and independently
graded by two of the authors [19].
Data analysis
Statistical analysis was performed using statistical package
SPSS for Windows, Release 13.0.1 (standard version;
SPSS, Inc., Chicago, IL). Significance levels for univariate
statistical test were determined by the Mann-Whitney U
test, χ2 test and Fisher exact test. A p value of 0.05 or less
was considered to be significant in all statistical tests used.
Results
Of the 340 subjects, 82 (24.1%) were women and 258
(75.9%) men. Mean age was 42.21 ± 10.35 years (range
16–86 years). One hundred and ninety four (57%) and
146 (43%) patients lived in urban and semirural- rural
areas, respectively. One hundred and ninety-six (57.6%)
patients consumed or had consumed intravenous drugs,
whilst 97 (28.5%) presented an excessive intake of alco-
hol. 13.8% of patients presented CD4 levels below or
equal to 200 cell/ml at the time of the study. Of all the
patients being followed-up, 102 (30%) had been diag-
nosed with AIDS. 50% of the patients were infected with
the hepatitis C virus, whereas only 5% was infected with
the hepatitis B virus (Table 1). None of the patients
enrolled in this study presented neither a past history of
diseases caused by exposure to Bartonella spp nor bar-
tonellosis symptoms. Antibodies to Bartonella species
were highly prevalent in this group of HIV patients; 76
(22.3%) of the samples reacted with at least 1 Bartonella
antigen, 32 (42.1%) of the positive samples reacted with
only B. henselae antigen, one sample (1.3%) reacted with
only B. quintana, and 43 (56.6%) with both. In 34 serum
samples, the titers obtained did not allow for differentia-
tion between the 2 Bartonella species, as the specimens
presented the same titer or one dilution as difference only.
In the 9 remaining serum samples, the titers obtained for
B. henselae were clearly superior (2 or more dilutions as
difference) (Table 2). Fifty-seven patients (75%) were pos-
itive at a titer of 1/64, 10 (13.1%) at 1/128, 5 (6.6%) at 1/
256, 2 patients (2.6%) at 1/512 and 2 patients (2.6%)
were positive at a titer of 1/1024. The antibody titer wasBMC Infectious Diseases 2008, 8:58 http://www.biomedcentral.com/1471-2334/8/58
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specific for B. quintana in one case only, with a titer of 1/
128.
24.4% of women and 21.7% of men presented antibodies
to  Bartonella spp. A statistically significant increase of
seropositivity against Bartonella spp. was observed as
patient age increased (p < 0.05). Twenty-three (30.2%)
patients with positive serology for Bartonella presented a
past history of alcohol abuse. Of the 76 patients with pos-
itive serology, 47 (61.8%) were addicted to parenteral
drugs and 22 (28.9%) had, at some time, being diagnosed
with AIDS. Thirty-nine patients presented co-infection
between Bartonella and HCV, whereas in 3 patients it was
between Bartonella and HBV. No differences were found
regarding the way of transmission of the human immun-
odeficiency syndrome.
Discussion
Preliminary estimates of the prevalence of antibody to
Bartonella among apparently healthy humans range from
5.88% to 24.7% [17,20]. In a study carried out on a
healthy population sample from the same area (83 were
men and 78 women, and the mean age with positive
serology was 45.18 ± 14.26 years), the seroprevalence was
10.6% [21], a figure that is very similar to that reported in
other studies. The incidence of Bartonella-associated dis-
ease among HIV- infected people is less known. The stud-
ies carried out show seroprevalence rates that range from
16 to 40% [18,22].
Epidemiological studies identified the major risk factors
for acquiring Bartonella infections. B. quintana infection is
associated with exposure to the human body louse, Pedic-
ulus humanus [13,23], and homeless conditions [23,24],
whereas the major risk factor associated with B. henselae
infection is cat exposure, especially cat scratches and fleas
Table 1: HIV patients description and serologic results
Characteristic N total (%) (340 patients) Positive to Bartonella N (%) (76 
patients)




Female 82 (24.1) 20 (26.3) 62 (24.4)
Male 258 (75.9) 56 (73.7) 202 (78.3)
Immunitary state 0.368
≤ 200 cell/ml 47 (13.8) 7 (9.2) 40 (15.2)
> 200 cell/ml 293 (86.2) 69 (90.8) 224 (84.8)
AIDS 1 0.820
Yes 102 (30) 22 (28.9) 80 (30.3)
No 238 (70) 54 (71.1) 189 (69.7)
Drugs abuse 0.401
Yes 196 (57.6) 47 (61.8) 149 (56.4)
No 144 (42.4) 29 (38.2) 115 (43.6)
Alcohol 0.704
Yes 97 (28.5) 23 (30.2) 74 (28.0)
No 243 (71.5) 53 (69.7) 190 (72)
HBV 2,3 17 (5) 3 (3.94) 14 (5.3) 0.449
HCV4 170 (50) 39 (51.3) 37 (48.7) 0.795
Municipality (inhab) 0.667
>50000 194 (57.0) 45 (59.2) 149 (56.4)
<50000 146 (43.0) 31 (40.8) 115 (43.6)
Transmission group 0.390
Heterosexual 62 (18.2) 11 (14.5) 51 (19.3)
Homosexual 15 (4.4) 1 (1.3) 14 (5.3)
IDU 5 194 (57.1) 47 (61.8) 147 (55.7)
Bisexual 5 (1.5) 2 (2.6) 3 (1.1)
Vertical 3 (0.9) 0 (0) 3 (0.9)
Unknown 61 (18) 15 (19.7) 46 (17.4)
1: AIDS criteria: Centers for Disease Control and Prevention (CDC) category C; 2: Hepatitis B virus infection; 3: Fisher Exact test; 4: Hepatitis C 
virus infection ; 5: Injection drug user.
Table 2: Pattern of IgG antibody titers to B. henselae and B. 
quintana in the study population (N= 340)
B. quintana titers
B. henselae titers <1/64 1/64 1/128 1/256
<1/64 264 0 1 0
1/64 28 29 0 0
1/128 4 6 0 0
1/256 1 5 0 0
1/512 0 1 1 0
1/1024 0 0 1 1BMC Infectious Diseases 2008, 8:58 http://www.biomedcentral.com/1471-2334/8/58
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[13,25-27]. B. henselae seroprevalence in cats in our area
was 29.6%, this result confirmed the presence of infection
in the main reservoir of this microorganism [28].
B. henselae infection, as in other infections caused by fas-
tidious bacteria, gives rise for concern given the complex-
ity of the diagnosis and the variety of presenting clinical
pictures, mainly in HIV-infected patients [29]. In fact, coe-
taneous BA lesions can be clinically indistinguishable
from Kaposi's sarcoma, being differentiated by biopsy
only. Hepatic disease caused by Bartonella can be indistin-
guishable from others infectious or malignant conditions
that cause hypodense lesions demonstrable by abdominal
CT [30]. All these factors make serology as a useful tool for
the diagnosis of acute infections caused by Bartonella spp.
However, it must be taken into account that there can be
important limitations when dealing with HIV infected
patients [31,32]. The serologic response in patients HIV
with a good immunological status could be similar to that
of the normal population, whereas possibly in situations
of advanced immunodepression or in bacillary angioma-
tosis, the serologic response could show as a false negative
[33].
Our study highlights in the first place an antibody sero-
prevalence of 22.4% to Bartonella species in HIV patients,
which is superior to that observed in the healthy popula-
tion [13,19,25], with the exception of that described in
some other studies [25]. Some authors consider HIV
patients as a risk group for Bartonella infection [34,35]
(characteristic personal and hygienic habits); however,
other authors do not consider this infection risk to be
greater [20,34].
In our experience, a previous study carried out on a
healthy population sample from the same area show a
seropositive rate of 8.6% [21]. This study included 55 chil-
dren and 161 adults (≥ 18 years). If children were not con-
sidered, the seroprevalence was 10.6%. In view of our
HIV-infected patients, predominantly adult, seems to be
higher, it could be considered HIV-infection as a risk fac-
tor.
Taking into account other studies, this difference among
populations might be due to the fact that in HIV patients
the infection can last longer or that these patients might
become in contact more easily with some of the factors
that have a direct impact on increased Bartonella infection,
such as contact with cats (main reservoir of B. henselae)
[16,17,24] or that they spend most of their time on the
street [24,34]. However, these informations are not avail-
able in our study. We could attribute the high rate of sero-
positivity observed to false positives that are not directly
due to HIV infection (to date no crossed- reactions have
been observed between both); however, there are studies
describing crossed reactions with Coxiella burnetii [32,35].
On the other hand, other studies suggest that HIV-infected
patients present a higher risk of Q fever than immuno-
competent patients [36]. The different factors that might
play an important role in the transmission of Bartonella
spp must also be taken into account. 57.6% of seroposi-
tive patients were intravenous drug users, these findings
are most likely a result of several conditions that are fre-
quent among IVDUs: living conditions with a high prob-
ability of close contact with bacteriaemic cats, fleas, lice,
and other potential vectors, repeated parenteral expo-
sures, insufficient medical care, and malnutrition
[19,33,34,37]. Other studies do not conclude that drug
use might play such an important role [20].
An excessive consumption of alcohol constitutes an ele-
vated risk factor for infection, not only for its capacity to
physiologically deteriorate regular alcohol abusers (liver
alterations, neurological disorders, etc.), but because in
the majority of cases drinking can affect people at low
socioeconomic levels (homeless) who might be in closer
contact with infection-transmitting vectors [38,39].
Of special interest in these patients was to find out
whether the risk for infection increased with immunode-
pression. In our experience, we were unable to detect a
greater incidence among patients who had been diag-
nosed with AIDS at some given time. In like manner, we
were also unable to detect a greater infection incidence in
patients with levels < 200 lymphocytes CD4/μl, in con-
trast with what has been reported by some authors who
claim that the prevalence of antibodies against B. henselae
is inversely proportional to the number of CD4 lym-
phocytes [30,35].
Our study presented only a 13.8% of patients with low
CD4 levels, which could significantly alter our results. If
we take into account that HIV-induced immunodepres-
sion does not appear to significantly modify the serologi-
cal response to Bartonella spp., serology could be useful in
the diagnosis of diseases associated with these microor-
ganisms in HIV-infected patients (acute infection and
population-based epidemiological studies). PCR tech-
niques might be of help to diagnose Bartonella infection in
patients who are more immunodepressed, especially
when the infection is subclinical. Bartonella infections are
substantially underrecognized because of their non-spe-
cific symptomatology.
Conclusion
In conclusion, the seroprevalence of Bartonella  spp.
among HIV infected patients is greater than that of the
healthy population of the same area and thus Bartonella
infection should be considered in HIV patients.BMC Infectious Diseases 2008, 8:58 http://www.biomedcentral.com/1471-2334/8/58
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